Browsing Tag
GlaxoSmithKline
31 posts
4DMedical (ASX: 4DX) jumps 13% as SimonMed rollout nears
4DMedical has record scans and A$278m cash, but its A$2.2bn value now depends on turning SimonMed’s US network into paid CT:VQ revenue.
CMP-002 trial clearance unlocks $50m as CAMP4 enters first-in-human stage
CAMP4 unlocks up to $50 million after Australian clearance for its CMP-002 trial, strengthening runway while creating major dilution.
HLN share price firms as Sensodyne and Centrum drive Haleon’s 2026 organic growth recovery
Sensodyne grows 8%. Centrum targets GLP-1 users. The £500m buyback erases shares at sub-340p. Haleon's recovery hinges on Q2 cold and flu normalising.
Xero (ASX: XRO) stock up 8.55% as FY26 revenue jumps 31% and Anthropic AI deal lands
Xero (ASX: XRO) is down 56% over twelve months. FY26 revenue grew 31% and Melio drove US revenue 240% higher. The reset is now between investment phase and margin recovery.
4DMedical (ASX: 4DX) stock up 7.3% as Mayo Clinic adoption and GSK contract reset lung imaging story
Nuclear medicine VQ scans are a US$1 billion market. 4DMedical (ASX: 4DX) just landed Mayo Clinic, GSK, and Medicare. The question is now scan volume scaling speed.
Moderna faces fresh mRNA patent assault from CureVac as BioNTech tightens legal grip on COVID-19 vaccine royalties
Moderna just settled $950 million in mRNA litigation. Now BioNTech-owned CureVac wants Spikevax royalties too. The patent war is widening.
GSK dodges tariffs with a massive pricing pivot—but what’s the catch?
GlaxoSmithKline cuts drug prices in the U.S. and secures tariff relief under a new federal deal. Find out what this means for pharma's future pricing playbook.
GSK walks away from IDEAYA cancer assets: What went wrong with synthetic lethality?
GSK ends its partnership with IDEAYA on two oncology assets. Find out what this means for IDEAYA’s pipeline, stock sentiment, and future partnerships.
GSK’s B7-H3 ADC secures EU orphan drug status as it accelerates global lung cancer trials
GSK’s B7-H3-targeted ADC GSK’227 receives EU Orphan Drug Designation for small-cell lung cancer. Learn how it fits into the company’s expanding global trial program.
How AnaptysBio’s 2026 spin-off plan could reshape its pipeline, royalty flows, and stock outlook
Discover how AnaptysBio (NASDAQ: ANAB) plans to split into two focused companies to unlock hidden value and reshape its investment story.